CTOs on the Move

STI Technologies

www.smartsti.com

 
STI Technologies Limited (STI) is a health-care technology company that provides Canadian patients with greater choice and broader access to the best medications and health care products.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.smartsti.com
  • 38 Solutions Drive Suite 200

    Halifax, NS CAN B3S 0H1
  • Phone: 902.450.5500

Executives

Name Title Contact Details

Similar Companies

4D Pharmacy Management Systems Inc

4D Pharmacy Management Systems Inc is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ria Health

Ria Healths at-home program uses technology, anti-craving medication & online coaching to help you reduce or quit drinking. Change your habits today.

Ascend Laboratories

Ascend Laboratories is a Montvale, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

InflaRx

InflaRx (Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany as well as Ann Arbor, Michigan. InflaRx is listed on the Nasdaq Global Select Market in the United States under the trading symbol “IFRX”.

Edesa Biotech Incorporated

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.